BCIQ Profiles

Company Profile Report
0329 bluebird
BioCentury & Getty Images


FDA approval solidifies bluebird’s anti-BCMA CAR T as ‘cornerstone’ of BMS’s multiple myeloma portfolio

Could help BMS get ahead of upcoming patent cliffs

Mar 27, 2021 | 5:05 AM GMT

FDA’s approval late Friday of Abecma idecabtagene vicleucel marks the second CAR T cell therapy BMS will bring to market as it continues to fill out its cancer portfolio ahead of revenue losses from upcoming patent cliffs. 

Patent expirations for

Read the full 711 word article

How to gain access

Continue reading with a
two-week free trial.